By Andreas Schreiner
Medical science is making significant advances in treating schizophrenia, but for all the progress we’ve seen, patients don’t benefit much unless they regularly take their medications. Second-generation (or atypical) long-acting injectable antipsychotic treatments (LATs) that ensure consistent administration of medication have become widely available over the past 15 years, but they remain a tough sell for many patients and psychiatrists.
And then there’s the prevalence of associated symptoms with schizophrenia that antipsychotic drugs don’t treat. Managing these symptoms is essential to improving patient outcomes but remains an elusive goal, even after decades of progress.
Continue reading to learn more about the pros and cons of long-acting injectable antipsychotic treatments (LATs)and how LATs can address the associated symptoms of schizophrenia.